

nature biotechnology

EDITORIAL

1313 Yes we can as well

NEWS

- 1315 FDA launches priority vouchers for neglected-disease drugs
- 1317 Ustekinumab poised to enter the psoriasis market
- 1317 German BioPharma awards
- 1319 Europe lags, US leads in 2nd-generation biofuels
- 1320 Oslo's cancer leap
- 1320 Cell/gene potency guides
- 1322 California bill abets biotech
- 1322 Biomarkers' double edge
- 1322 Shire dumps Dynepo
- 1323 Country-of-origin labels
- 1323 Giants wrestle over ImClone
- 1325 PROFILE: Alan Alda
- 1326 DATA PAGE: Biotech patents—business as usual
- 1327 NEWS FEATURE: Hypertension's shot in the arm

BIOENTREPRENEUR


BUILDING A BUSINESS

- 1331 Moving on
Jennie Mather

OPINION AND COMMENT

CORRESPONDENCE

- 1335 Protest and 'democracy'
- 1335 Foot and Mouth's Achilles' heel?
- 1336 Automated *de novo* protein sequencing of antibodies
- 1339 PhosphoPep—a database of protein phosphorylation sites in model organisms



Artist's impression of an integrated blood barcode chip for rapid, multiplexed detection of biomarkers. Fan *et al.* separate plasma from whole blood in a microfluidic device that captures proteins of interest using antibodies immobilized by DEAL technology and detects them using fluorophore-labeled antibodies (p 1373). Credit: Ken Eward ©BioGrafx.




Kickstarting drug development against malaria and other neglected diseases, p 1315




nature publishing group


Nature Biotechnology (ISSN 1087-0156) is published monthly by Nature Publishing Group, a trading name of Nature America Inc. located at 75 Varick Street, Fl 9, New York, NY 10013-1917. Periodicals postage paid at New York, NY and additional mailing post offices. **Editorial Office:** 75 Varick Street, Fl 9, New York, NY 10013-1917. Tel: (212) 726 9335, Fax: (212) 696 9753. **Annual subscription rates:** USA/Canada: US\$250 (personal), US\$2,730 (institution), US\$4,050 (corporate institution). Canada add 7% GST #104911595RT001; Euro-zone: €202 (personal), €2,170 (institution), €3,488 (corporate institution); Rest of world (excluding China, Japan, Korea): £130 (personal), £1,400 (institution), £2,250 (corporate institution); Japan: Contact NPG Nature Asia-Pacific, Chiyoda Building, 2-37 Ichigayatamachi, Shinjuku-ku, Tokyo 162-0843. Tel: 81 (03) 3267 8751, Fax: 81 (03) 3267 8746. **POSTMASTER:** Send address changes to *Nature Biotechnology*, Subscriptions Department, 342 Broadway, PMB 301, New York, NY 10013-3910. **Authorization to photocopy** material for internal or personal use, or internal or personal use of specific clients, is granted by Nature Publishing Group to libraries and others registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided the relevant copyright fee is paid direct to CCC, 222 Rosewood Drive, Danvers, MA 01923, USA. Identification code for *Nature Biotechnology*: 1087-0156/04. **Back issues:** US\$45, Canada add 7% for GST. CPC PUB AGREEMENT #40032744. Printed by Publishers Press, Inc., Lebanon Junction, KY, USA. Copyright © 2008 Nature Publishing Group. Printed in USA.



Microfluidic blood analysis, p 1345



ChIP-Seq data analysis, p 1351

Genomic changes in hES cells,
p 1361 and p 1364

FEATURE

PATENTS

- 1341 Antibody patenting without antibodies: a global trend**
Kazunori Hashimoto & Tomomi Aida
- 1344 Recent patent applications in protein purification**

NEWS AND VIEWS

- 1345 Microfluidics closes in on point-of-care assays**
Peter K Sorger  see also p 1373
- 1346 MicroRNAs fine-tune oncolytic viruses**
John C Bell & David Kirn
- 1348 Cancer and complement**
Suzanne Ostrand-Rosenberg
- 1350 RESEARCH HIGHLIGHTS**

COMPUTATIONAL BIOLOGY

ANALYSIS

- 1351 Design and analysis of ChIP-seq experiments for DNA-binding proteins**
Peter V Kharchenko, Michael Y Tolstorukov & Peter J Park


RESEARCH

BRIEF COMMUNICATIONS

- 1361 Recurrent chromosomal abnormalities in human embryonic stem cells**
C Spits, I Mateizel, M Geens, A Mertzanidou, C Staessen, Y Vandekelde, J Van der Elst, I Liebaers & K Sermon
- 1364 Human embryonic stem cells reveal recurrent genomic instability at 20q11.21**
N Lefort, M Feyeux, C Bas, O Féraud, A Bennaceur-Griscelli, G Tachdjian, M Peschanski & A L Perrier

ARTICLE

- 1367 MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification**
J Cox & M Mann



Mass spectrometry platform, p 1367

LETTERS

1373 Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of bloodR Fan, O Vermesh, A Srivastava, B K H Yen, L Qin, H Ahmad, G A Kwong, C-C Liu, J Gould, L Hood & J R Heath  *see also p 1345***1379 Asymmetric RNA duplexes mediate RNA interference in mammalian cells**

X Sun, H A Rogoff & C J Li

1383 ERRATA**NATUREJOBS BIOTECHNOLOGY****CAREERS AND RECRUITMENT****1385 Development translates discoveries into products**

Mark Johnson

NATURE BIOTECHNOLOGY CLASSIFIED

See back pages.

1388 PEOPLE

```

CUGAUAUUUGAUG
CAUCGACUAUAACUACUGAA
CUGAUAUUUGAUGG
CAUCGACUAUAACUACUGAA
GCUGAUAUUUGAUGG
CAUCGACUAUAACUACUGAA
CUGAUAUUUGAUGGA
CAUCGACUAUAACUACUGAA
GCUGAUAUUUGAUGGA
CAUCGACUAUAACUACUGAA

```

New scaffold for siRNA, p 1379

ADVERTISEMENT**Biotech Locations**

Clusters of biotech companies, from start-ups to big companies, are growth centers for the industry. But how did they form, and is it still possible to purposefully create them today? This special report follows Letters after page 1382 and is produced with commercial support from the organizations featured in the Advertorial Profiles.

